Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A rearrange |
Therapy | Decitabine + FHD-286 |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | sensitive | Decitabine + FHD-286 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of FHD-286 and Dacogen (decitabine) synergistically inhibited viability of acute myeloid leukemia cell lines harboring a KMT2A rearrangement in culture (PMID: 38437498). | 38437498 |
PubMed Id | Reference Title | Details |
---|---|---|
(38437498) | BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. | Full reference... |